Inactive Instrument

Diplomat Pharmacy, Inc.

DPLO

Diplomat Pharmacy, Inc. Announces Updated 2016 Financial Guidance

January 09, 2017 at 06:00 am EST

Diplomat Pharmacy, Inc. announced updated 2016 financial guidance. The company now expects 2016 revenue and adjusted EBITDA will be at or near the low end of previously announced ranges. In 2016, Affinity Biotech generated an estimated $27 million in revenue and $3 million in adjusted EBITDA.

Latest news about Diplomat Pharmacy, Inc.

Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 600 Health Care	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 1000	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 600	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P Composite 1500	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P 600 Health Care Services (Sub Ind)	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P TMI Index	20-02-13	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P Global BMI Index	20-02-13	CI
OptumRx, Inc. completed the acquisition of Diplomat Pharmacy, Inc. from Hagerman and others.	20-02-06	CI
Walgreen Co. acquired Certain Records of Diplomat Pharmacy, Inc. for $0.5 million.	19-12-22	CI
OptumRx, Inc. entered into an agreement to acquire Diplomat Pharmacy, Inc. from Hagerman and others for approximately $320 million.	19-12-08	CI
Transcript : Diplomat Pharmacy, Inc., Q3 2019 Earnings Call, Nov 12, 2019	19-11-12
Diplomat Pharmacy, Inc. Revises Earnings Guidance for the Full-Year 2019; Reports Impairments for the Third Quarter Ended September 30, 2019	19-11-12	CI
Diplomat Pharmacy, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Diplomat Pharmacy Continues to Pursue Comprehensive Strategic Alternatives Process	19-11-12	CI
Diplomat Pharmacy, Inc. Announces Executive Changes	19-10-02	CI
Transcript : Diplomat Pharmacy, Inc., Q2 2019 Earnings Call, Aug 09, 2019	19-08-09
Diplomat Pharmacy, Inc. Revises Earnings Guidance for the Full Year of 2019	19-08-09	CI
Diplomat Pharmacy, Inc. Reports Goodwill Impairments for the Second Quarter Ended June 30, 2019	19-08-09	CI
Diplomat Pharmacy, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-09	CI
Diplomat Announces Review Of Strategic Alternatives	19-08-09	CI
Diplomat Pharmacy, Inc. Signs Exclusive Practice-Based Infusion Agreement with Allergy Partners	19-08-08	CI
Diplomat Pharmacy, Inc.(NYSE:DPLO) dropped from S&P Health Care Services Select Industry Index	19-06-24	CI
Transcript : Diplomat Pharmacy, Inc., Q1 2019 Earnings Call, May 07, 2019	19-05-07
Diplomat Pharmacy, Inc. Provides Earnings Guidance for the Full Year of 2019	19-05-07	CI
Diplomat Pharmacy, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-07	CI

Chart Diplomat Pharmacy, Inc.

Duration

Period

More charts

Company Profile

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

Sector

Drug Retailers

More about the company

Sector Other Drug Retailers

	1st Jan change	Capi.
WALGREENS BOOTS ALLIANCE, INC.	-33.99%	14.86B
JD HEALTH INTERNATIONAL INC.	-23.66%	11.73B
YIFENG PHARMACY CHAIN CO., LTD.	+12.44%	6.3B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED	-25.24%	6.29B
MATSUKIYOCOCOKARA & CO.	-9.39%	6B
NAHDI MEDICAL COMPANY	-2.34%	4.63B
CORPORATIVO FRAGUA, S.A.B. DE C.V.	+60.00%	4.57B
DASHENLIN PHARMACEUTICAL GROUP CO., LTD.	-10.84%	3.5B
WELCIA HOLDINGS CO., LTD.	-6.41%	3.04B

Other Drug Retailers